Manama, April 16 (BNA) The Gulf Biotechnology Company has become the second pharmaceutical manufacturing facility in the Kingdom of Bahrain.
The National Health Regulatory Authority, announced that it has licensed the medical company, which is also the first injectable drug manufacturing facility in the Kingdom of Bahrain.
Thus, the factory has obtained the rights to produce the initial batches of injectable drugs after submitting studies for the products produced and confirming successful stability analyzes for them.
Injectable medicines will also undergo final examination to be awarded Good Manufacturing Practices (GMP) certification to begin production and marketing of sterile and injectable formulations.
“The factory was licensed after meeting the conditions related to security, safety and quality in accordance with international standards,” said Dr. Mariam Al Jalahma, CEO of the authority.
She stressed Bahrain’s commitment to international standards related to the pharmaceutical industry, adding that all projects will be subject to the highest requirements of security, safety and quality and are mandatory in this important field.
The licensed factory will manufacture a variety of injectable human healthcare formulations such as vials, ampoules and prefilled syringes using the highest and best German technology from BOSCH.
Gulf Biotechnology is headquartered in the Bahrain International Investment Park (BIIP) in the Hidd Industrial Area, and consists of three floors covering approximately 4,500 square metres.
in the current situation. Dr. Riyadh Al-Ashban said that the Gulf Biotechnology Company will be the first of its kind in the Middle East in the production of injectable drugs, using production lines with very high technology produced by the German company Bosch (isolation system).
“This advanced technology ensures complete technical work without human intervention,” he said, expecting the plant to start production in the first phase of 56 basic pharmaceutical products during 2022.
insult